Enright Patrick G's Form 4 filing
Vera Therapeutics, Inc.VERA · filed Jun 25, 2025
- Accession no.
- 0000950170-25-090110
- Filed
- Jun 25, 2025
- Trade date
- Jun 23-24, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions. Open-market purchases total $5.28M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Enright Patrick GCIK 0001253886 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 23, 2025 | Class A Common Stock | PPurchaseAcquired | +69,798 | $20.87F1 | +$1,456,684.26 | 1,784,083 | Indirect | |
| Jun 23, 2025 | Class A Common Stock | PPurchaseAcquired | +139,595 | $20.87F1 | +$2,913,347.65 | 3,569,522 | Indirect | |
| Jun 24, 2025 | Class A Common Stock | PPurchaseAcquired | +13,536 | $22.35F4 | +$302,529.6 | 1,797,619 | Indirect | |
| Jun 24, 2025 | Class A Common Stock | PPurchaseAcquired | +27,071 | $22.35F4 | +$605,036.85 | 3,596,593 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $20.43 to $21.05, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4.
Referenced by the price of 2 transactions in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $21.67 to $22.50, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 4 to this Form 4.
Referenced by the price of 2 transactions in Table I.